Compare Lockheed Martin Corporation (LMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Lockheed Martin Corporation trades at $508.27 (market cap $117.22B), while State Street SPDR S&P Biotech ETF trades at $153.82 (market cap $10.11B). The key difference: Lockheed Martin Corporation is far larger — about 11.6× State Street SPDR S&P Biotech ETF's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LMT | XBI | |
|---|---|---|
Market Cap | $117.22B | $10.11B |
Volume | 1,101,121 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $676.70 | $169.55 |
52-Week Low | $439.19 | $104.99 |
Typical Hold Time | 86 Days | 38 Days |
Enterprise Value | $133.96B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $508.18, up 1.79% with a bearish technical signal despite recent earnings beat. The defense contractor shows strong fundamentals with $75.05B revenue, 8.16% net margin, and robust cash flow of $8.56B from operations. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains bullish with a $635.33 price target representing 25% upside potential.
LMT presents a compelling value opportunity with attractive valuation multiples (P/E 18.73, P/S 1.53) and 23-year dividend growth streak. Key risks include dependency on Pentagon contracts and fixed-price contract volatility. The stock's current discount to analyst targets and defensive positioning in aerospace/defense sector support long-term investment case despite near-term technical weakness.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
